

- 100.09.07署授食字第1001404972號公告。
6. 行政院衛生署中華藥典編修委員會。2011。中華藥典。第七版。行政院衛生署藥物食品檢驗局，台北。
 7. Lacy, C. F., Armstrong, L. L., Goldman, M. P. and Lance, L. L. 2001. Drug Information Handbook 2001-2002. 9th Ed. Lexi Comp. OH, USA.
 8. Thomson Reuters Micromedex 2.0. [<http://www.micromedex.com/>].
 9. Katzung, B. G. 2007. Basic and Clinical Pharmacology. 10th Ed. McGraw-Hill Medical. USA.
 10. Schumacher, G. E. 1995. Therapeutic Drug Monitoring. Appleton & Lange. USA.

Investigation on the Quality of Marketed Carbamazepine Tablets in Taiwan Area

CHEN-YUAN WU, ZONG-HAN YUE, YA-LING SU, POR-YUH WANG,
YU-PEN CHEN AND DANIEL YANG-CHIH SHIH

Division of Research and Analysis, FDA

ABSTRACT

Carbamazepine (CBZ) is the preferred agent for the treatment of trigeminal neuralgia and seizure disorders. However, CBZ frequently causes cutaneous adverse drug reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In order to survey the quality of the marketed carbamazepine tablets in Taiwan area, 7 samples were collected from different counties and/or cities in Taiwan during March thru May 2011. Samples were analyzed by the previously approved analytical method. The result showed that 6 samples met the requirements. One sample failed to fulfill the dissolution test requirements.

Key words: carbamazepine (CBZ), dissolution test, extended-release tablets, quality